CymaBay Therapeutics (NASDAQ:CBAY) versus Nature’s Sunshine Products (NASDAQ:NATR) Head-To-Head Contrast

CymaBay Therapeutics (NASDAQ:CBAYGet Free Report) and Nature’s Sunshine Products (NASDAQ:NATRGet Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Risk and Volatility

CymaBay Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Nature’s Sunshine Products has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Valuation & Earnings

This table compares CymaBay Therapeutics and Nature’s Sunshine Products’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CymaBay Therapeutics $31.07 million 118.82 -$105.37 million ($0.97) -33.18
Nature’s Sunshine Products $421.91 million 0.81 -$390,000.00 $0.41 43.90

Nature’s Sunshine Products has higher revenue and earnings than CymaBay Therapeutics. CymaBay Therapeutics is trading at a lower price-to-earnings ratio than Nature’s Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CymaBay Therapeutics and Nature’s Sunshine Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CymaBay Therapeutics N/A -50.72% -31.04%
Nature’s Sunshine Products 1.84% 7.94% 5.02%

Analyst Recommendations

This is a breakdown of recent recommendations for CymaBay Therapeutics and Nature’s Sunshine Products, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CymaBay Therapeutics 0 11 2 0 2.15
Nature’s Sunshine Products 0 0 1 0 3.00

CymaBay Therapeutics presently has a consensus price target of $27.14, indicating a potential downside of 15.67%. Nature’s Sunshine Products has a consensus price target of $21.50, indicating a potential upside of 19.44%. Given Nature’s Sunshine Products’ stronger consensus rating and higher probable upside, analysts clearly believe Nature’s Sunshine Products is more favorable than CymaBay Therapeutics.

Insider and Institutional Ownership

95.0% of CymaBay Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of Nature’s Sunshine Products shares are owned by institutional investors. 7.0% of CymaBay Therapeutics shares are owned by insiders. Comparatively, 5.4% of Nature’s Sunshine Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Nature’s Sunshine Products beats CymaBay Therapeutics on 10 of the 14 factors compared between the two stocks.

About CymaBay Therapeutics

(Get Free Report)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

About Nature’s Sunshine Products

(Get Free Report)

Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. The company was founded in 1972 and is headquartered in Lehi, Utah.

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.